Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease
D. Lillicrap
1
Departments of Pathology and Medicine, Queen’s University, Kingston, Ontario
,
M.-C. Poon
2
Departments of Medicine, Pediatrics and Oncology, University of Calgary, and the Canadian Blood Services, Calgary, Alberta
,
I. Walker
3
Dept. of Medicine, McMaster University Medical Centre, Hamilton, ON
,
F. Xie
4
Aventis-Behring, Ottawa, ON, Canada
,
B.A. Schwartz
4
Aventis-Behring, Ottawa, ON, Canada
,
members of the Association of Hemophilia Clinic Directors of Canada› Institutsangaben